ロード中...

Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase

Despite the success of imatinib at inhibiting Bcr-Abl and treating chronic myelogenous leukemia (CML), resistance to the therapy occurs over time in patients. In particular, the resistance to imatinib caused by the gatekeeper mutation T315I in Bcr-Abl remains a challenge in the clinic. Inspired by t...

詳細記述

保存先:
書誌詳細
出版年:J Med Chem
主要な著者: Liu, Xu, Kung, Alvin, Malinoski, Brock, Prakash, G. K. Surya, Zhang, Chao
フォーマット: Artigo
言語:Inglês
出版事項: 2015
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7475166/
https://ncbi.nlm.nih.gov/pubmed/26562217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.5b01125
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!